Expression of MeCP2 must be carefully regulated as a reduction or increase results in serious neurological disorders. We are studying transgenic mice in which the MeCP2 gene is expressed at about three times higher than the normal level. Male MeCP2-Tg mice, but not female mice, suffer motor and cognitive deficits and die at 18-20 weeks of age. MeCP2-Tg mice display elevated GFAP and Tau expression within the hippocampus and cortex followed by neuronal loss in these brain regions. Loss of Purkinje neurons, but not of granule neurons in the cerebellar cortex is also seen. Exposure of cultured cortical neurons to either conditioned medium from astrocytes (ACM) derived from male MeCP2-Tg mice or normal astrocytes in which MeCP2 is expressed at elevated levels promotes their death. Interestingly, ACM from male, but not female MeCP2-Tg mice, displays this neurotoxicity reflecting the gender selectivity of neurological symptoms in mice. Male ACM, but not female ACM, contains highly elevated levels of glutamate, and its neurotoxicity can be prevented by MK-801, indicating that it is caused by excitotoxicity. Based on the close phenotypic resemblance of MeCP2-Tg mice to patients with MECP2 triplication syndrome, we suggest for the first time that the human syndrome is a neurodegenerative disorder resulting from astrocyte dysfunction that leads to Tau-mediated excitotoxic neurodegeneration. Loss of cortical and hippocampal neurons may explain the mental retardation and epilepsy in patients, whereas ataxia likely results from the loss of Purkinje neurons.
Introduction
Methyl-CpG-binding protein 2 (MeCP2) is a protein that binds to methylated DNA and regulates chromatin structure, transcription, and splicing [1] [2] [3] . Although ubiquitously expressed, MeCP2 is most abundantly produced in the brain where it is expressed primarily in postmitotic neurons. The role of MeCP2 in neuronal or brain function is not well understood and the subject of intense investigation [2, 4] . Loss of M e C P 2 f u n c t i o n c a u s e s R e t t s y n d r o m e , a neurodevelopmental disorder primarily affecting females (because the gene is X-linked) [5, 6] . Unexpectedly, increased MeCP2 expression resulting from gene duplication or triplication causes a different and more severe neurological disorder called MECP2 duplication or MECP2 triplication syndrome ( [7] [8] [9] ). Males with this syndrome display severe mental retardation, motor deficits, epilepsy, progressive spasticity, and premature death. Macrocephaly is observed in more severe cases of MECP2 duplication syndrome and with MECP2 gene triplication [7] [8] [9] [10] . Non-neurological symptoms include constipation and recurrent infections [8] [9] [10] . Females with MECP2 gene triplications are often asymptomatic due to highly skewed X-chromosome inactivation. MRI scans of affected patients have revealed generalized cortical atrophy, loss of white matter, and mildly enlarged lateral ventricles indicating neuronal loss [9, 11, 12] . In one case where results of postmortem neuropathological analysis have been reported, diffuse neuronal loss in the cortex and minor disturbance of cortical lamination was observed [13] .
We have been studying a transgenic mouse line, MeCP2-Tg3, generated by Collins et al. in which the human MECP2 transgene is localized to the X chromosome and expressed from its own promoter [14] . The transgenic mice, henceforth referred to as MeCP2-Tg mice, express MeCP2 at about 3-fold higher than normal levels. Female transgenic mice appear normal while male transgenic mice display neurological deficits starting at around 6 weeks of age and have a severely shortened life span. We describe that MeCP2-Tg mice display selective neurodegeneration in the brain, affecting cortical neurons, hippocampal neurons, and Purkinje neurons of the cerebellum. Neuronal loss in the cortex and hippocampus is preceded by an upregulation of glial fibrillary acidic protein (GFAP) and of the microtubule-associated protein, Tau. It is noteworthy that increased expression of GFAP and Tau have both been found to be sufficient to promote neurodegeneration in Drosophila and mice [15] [16] [17] [18] . Results from cell culture experiments utilizing cultured MeCP2-Tg neurons and astrocytes indicate that neurodegeneration in MeCP2-Tg mice results from a disruption of glutamate homeostasis in astrocytes. This leads to an increase of Tau in neurons and their death by excitotoxicity.
Methods
Mice MeCP2-Tg3 mice were purchased from Jackson Laboratories (Bar Harbor, ME; stock number 008680, https://www.jax.org/strain/008680). Mice were housed in a temperature-, humidity-, and light-controlled room (12-h light/dark cycle, lights on 6:00 AM-6:00 PM). Food and water were available ad libitum. All procedures were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals as approved by the Southern Methodist University Institutional Animal Care and Use Committee (IACUC). Unless otherwise noted, all mice used in this study were male.
Genotyping Genotyping of MeCP2-Tg mice was performed as previously described [19, 20] . Briefly, DNA was extracted from mouse toe-clips using the REDExtract-N-Amp Tissue PCR Kit from Sigma-Aldrich (St. Louis, MO), and the DNA obtained was used in PCRs to determine genotype (MeCP2 transgene forward − 5′-CGCTCCGCCCTATCTCTGA-3′, MeCP2 transgene reverse − 5′-ACAGATCGGATAGAAGACTC-3′; MeCP2 internal positive control forward − 5′-CAAATGTTGCTTGT CTGGTG-3′, MeCP2 internal positive control reverse − 5′-GTCAGTCGAGTGCACAGTTT-3′).
Behavior
Open Field Open-field locomotor testing was conducted using the Truscan system from Coulbourn Instruments (Whitehall, PA) as previously described [21] .
Grip Strength The grip strength meter, purchased from San Diego Instruments (San Diego, CA), was used to assess neuromuscular functional differences by recording the peak force each mouse exerted by grasping a grip bar placed at the mouse's forelimbs or hindlimbs. For this test, mice were acclimated to the room for 15 min prior to testing, and then mice were allowed to grasp a grip bar and gently pulled backwards along a horizontal plane. Tension (grip strength (GS)) applied to the grip during the trial was recorded until the mouse lost its grip. Tests were repeated three consecutive times with the maximum peak tension recorded during each trial. Trials were then averaged for analysis.
ROTOR-ROD For training, animals were allowed to habituate to the testing room for 30 min in their home cages. Following a 5 min habituation to the stationary rod, the training program began with a speed of 5 r.p.m. In the event of a fall, subjects were placed back onto the rod until they had remained for a total of 300 sec. This training protocol was repeated for a total of three sessions with a 5 min break between each session. Training was repeated for three consecutive days. For testing, animals were habituated to the testing room as previously described. The testing program began at 0 r.p.m., increasing to 40 r.p.m. incrementally over 300 sec. Latency to fall was measured for each subject and recorded in ROTOR-ROD software (SD Instruments) and repeated for three trials with a 5 min break between each trial.
Y-maze Mice were allowed to habituate to the testing room for 30 min. After habituation, each mouse was then allowed to explore the A and B arms of the Y-maze for 15 min with the novel C arm blocked from exploration. After exploration, the Y-maze was cleaned and each mouse was then allowed to explore the A, B, and C arms of the Y-maze for 5 min while being video recorded. After testing, videos were scored for the number of entries into each arm, and then data was expressed as a percentage of entries into each arm during this 5 min time period.
Novel Object Mice were allowed to habituate to the testing room for 30 min. Following habituation, each mouse was placed in an open chamber with two identical objects and allowed to explore freely. After 10 min, the mouse was removed and the chamber and objects were cleaned. The mouse was then placed back in the chamber with one of the original objects and one new object and allowed to freely explore for 5 min while being video recorded. After testing, videos were scored for time spent exploring each object, and the data expressed as a ratio of the time spent exploring the novel object to the time spent exploring the familiar object. Object placement was randomized in order to mitigate potential place preference.
Western Blot Western blot analysis was conducted as previously described [21] . PVDF membranes were probed with the following antibodies: anti-MeCP2 (Cell Signaling, Beverly, MA; 1:1000, catalog number 3456S), anti-total Erk (Cell Signaling, 1:1000, catalog number 9102L), anti-NeuN (Cell Signaling, 1:1000, catalog number D4640), anti-GFAP (Cell Signaling, 1:1000, catalog number 3670), anti-Iba1 (Wako, Osaka, Japan; 1:500, catalog number 019-19741), antiglutamine synthetase (Millipore, Billerica, MA; 1:1000, catalog number MAB302), anti-Glast (EAAT1) antibody (Abcam, Cambridge, MA; 1:1000, catalog number ab416), anti-MAP2 (Sigma-Aldrich, St. Louis, MO; 1:500, M4403), anti-Tau46 (Cell Signaling, 1:1000, catalog number 4019), anti-α-tubulin (Sigma-Aldrich, 1:40000, catalog number T5168), anti-Tau RD4 (Millipore, 1:1000, catalog number 05-804), antipTau262 (Santa Cruz Biotechnology, Dallas, TX; 1:1000, catalog number sc-101813), and anti-pTau404 (Santa Cruz Biotechnology, 1:1000, catalog number sc-12952-R). The Glt1 antibody was a kind gift from Jeffrey Rothstein.
Histology Histology and histological analysis were conducted as previously described [21] . DAB staining was conducted using the Vectastain Elite ABC Kit (Burlingame, CA) following manufacturer's instructions. TUNEL staining was conducted using the TUNEL Kit from Promega (Madison, WI; catalog number G3250) following manufacturer's instructions. The following antibodies were used in histology: NeuN (Cell Signaling, 1:300, catalog number D4640), NeuN (Millipore, 1:300, catalog number MAB377), SATB2 (Abcam, 1:500, catalog number ab51502), CTIP2 (Abcam, 1:500, catalog number ab18465), Calbindin (Sigma-Aldrich, 1:400, catalog number C2724), GFAP (Dako, Carpinteria, CA, 1:500, catalog number Z0334), and Iba1 (Wako, 1:500, catalog number 019-19741).
RT-PCR RT-PCR analysis was performed as previously described [22] .
The primers used for PCR amplification are as follows:
GFAP forward 5′-GAGCGTGCAGAGATGATGGA-3′ GFAP reverse 5′-TCTCCTCCTCCAGCGATTCA-3′
Tau 4R and 3R primers:
Mouse exon 1F 58-5′-TCCGCTGTCCTCTTCTGTC-3′ Mouse exon 5R 58-5′-TTCTCGTCATTTCCTGTCC-3′
Tau 0N, 1N, and 2N primers:
Mouse exon 9R 58-5′-CACCAAAATCCGGAGAACG-3′
Mouse exon 11R 58-5′-CTTTGCTCAGGTCC ACCCGGC-3′
Isolation and Culture of Astrocytes From Mouse Cortex Astrocyte cultures were prepared from postnatal day 1 mouse pups. Prior to dissection, astrocyte culture media (DMEM, high glucose + 10% heat-inactivated fetal bovine serum + 1% penicillin/streptomycin) was prewarmed. The mouse brain was removed and placed in a dish of HBSS; the cortices were carefully dissected; and then, the meninges from the cortex hemispheres were removed by pulling with forceps. Each cortex was cut into small pieces and placed into a tube with HBSS and 2.5% trypsin. The cortical tissue was then incubated in a 37°C water bath for 12 min and was gently agitated every 2 min. After incubation, the tissue was centrifuged at 3000×g for 5 min. The supernatant was decanted and tissue was dissociated through pipetting in astrocyte culture media. After plating, the astrocyte culture media was changed every 2 days, and at 7 days, the astrocytes were split. Once the purity of the culture was determined through immunocytochemistry, the astrocytes were used for experiments.
Cortical Neuron Culture, Conditioned Media Treatment, and Live/Dead Assay Cortical cultures were prepared from embryonic day 17-18 rat pups as previously described [22, 23] . For generation of pure neuronal cultures, 18 h after plating, 1 μM Ara-C (cytosine arabinoside) was added to the wells to prevent the proliferation of glial cells. For generation of mixed neuronal cultures, the dissociated cells were plated in media containing 10% FBS to encourage the proliferation of glial cells. On day 5, 300 μl of media was removed from each well of cortical neurons in a 24-well plate and 400 μl of conditioned media was added. For MK-801 treatment, each well was pretreated for 20 min with MK801 and then conditioned media was added. After incubating neurons in conditioned media for 48 hr, neuronal viability was determined using the Live/Dead Cytotoxicity Kit (Invitrogen; Carlsbad, CA) according to manufacturer's instructions.
Experimental Design and Statistical Analysis All cell culture and biochemical experiments were performed at least three times. For viability measurements, each experiment was performed in duplicate and repeated at least thrice. All in vivo experiments, including behavioral analyses, were performed using a minimum of six mice per condition and genotype. All statistical analyses were done using GraphPad Prism s o f t w a r e . D a t a w a s a n a l y z e d b y a n u n p a i r e Although variability between mice is observed, male MeCP2-Tg mice express MeCP2 at levels that are 3.3 times higher that their wild-type littermates (Fig. 1a-c) . This is consistent with information provided by Jackson Labs, which indicates that the transgene is expressed at three to five times the normal level (https://www.jax.org/strain/008680). An initial characterization of MeCP2-Tg mice has been previously reported [14] . Hypotonia, seizures, anxiety, and social behavior deficits, commonly seen in patients with MECP2 duplication/ triplication syndrome, were described in that study [14] . We have extended the characterization. As observed in patients, male MeCP2-Tg mice appear normal at birth but display neurological abnormalities subsequently. Forepaw clasping is observed by 6 weeks of age ( Fig. 2a) as is reduced hindlimb strength ( Fig. 2b) . No reduction is seen in forelimb strength, however ( Fig. 2c ). Reduced motor ability at 6 weeks is confirmed using the ROTOR-ROD assay (Fig. 2d ). Open-field locomotor tests reveal normal locomotion at 6 weeks but reduction at 9 weeks (Fig. 2e) . Cognitive impairment was also revealed in Y-maze tests ( Fig. 2f ) and in the novel object recognition test (Fig. 2g ). Ataxia and obvious movement deficits are observed at around 15 weeks. The neurological deficits are progressive and the mice die at 18-20 weeks. Macrocephaly has been reported in patients with MECP2 triplication syndrome. MeCP2-Tg mice also display reduction in body weight, increase in brain weight, and increase in body to brain weight ratio ( Fig. 2h-j) . Life span, brain weight, body weight, and behavioral performance are normal in female MeCP2-Tg mice (Supplemental Fig. 1 ). We have found that, like patients [24] , MeCP2-Tg mice display signs of constipation (data not shown). Taken together, our results along with those described previously [14] demonstrate that MeCP2-Tg mice faithfully recapitulate the major abnormalities of MECP2 triplication syndrome.
Delayed Neuronal Loss in MeCP2-Tg Mice We performed immunohistochemistry with two different antibodies against NeuN. No difference in the pattern of staining or number of NeuN-positive cells between MeCP2-Tg mice and wild-type littermates is observed in the cortex, hippocampus, striatum, or cerebellum, at 10 weeks of age ( Fig. 3) . At 12 weeks, however, a slight reduction in the number of NeuN-positive cells is detectable in the cortex, and by 15 weeks, a 29.3% reduction is observed in the somatomotor region of the cortex (Fig. 4a, c,  d ) and a 24.4% reduction in the CA1 region of the hippocampus ( Fig. 4b-d) .
Results showing reduced NeuN-positive cell numbers in the cortex and hippocampus obtained using fluorescence-based immunohistochemistry were confirmed using 3,3′-diaminobenzidine (DAB) staining (Fig. 4e) .
Western blots further confirmed that NeuN levels in the whole cortex and hippocampus are normal at 10 weeks but are reduced at 15 weeks ( Fig. 3e and 4f , respectively). We did not observe a significant change in NeuN-positive cell numbers or level of NeuN expression in the cerebellum (Fig. 3d , e, respectively). Expression of a neuron-specific form of β-tubulin, β-III tubulin, is also reduced in the cortex and hippocampus of MeCP2-Tg mice confirming that loss of neurons, rather than a reduction of NeuN or β-III tubulin expression, is responsible for the reduction in immunostaining (not shown). We extended our analyses using antibodies to CTIP2 and SATB2, two transcription factors that are expressed in specific cell populations in the developing and mature brain [25] . In the mature cortex, CTIP2 stains deep-layer projection neurons, whereas SATB2 stains superficial layers preferentially. While SATB2-positive neurons in layers II and III of the somatomotor cortex are reduced by 21.4% in MeCP2-Tg mice at 15 weeks, CTIP2-positive neurons in layers V and VI are reduced by only 6.13%, suggesting that upper layer neurons are selectively lost in the transgenic brain ( Fig. 4a, b) . Within the CA1 region of the hippocampus, there is a loss of 13.9% of CTIP2-positive neurons (Fig. 5b) . No cell loss is discernible in the striatum and other neuronal populations of the hippocampus at 15 weeks, suggesting selectivity in vulnerability to elevated MeCP2 (Fig. 4c, d ). In the cerebellum, the molecular and internal granule layer appears normal. However, there is obvious loss of Purkinje neurons, which is more noticeable in the posterior lobes, particularly lobe VII (Fig. 5c ). Regional differences in neurodegeneration within the cerebellum have been noted in various spontaneous mouse mutants, including the leaner and tottering mutants, as well as genetically engineered mouse mutants [26] . Selective cell loss in the upper cortical layers and hippocampus was confirmed at 15 weeks using DAPI staining to detect pyknotic nuclei and TUNEL staining to detect apoptotic cells (Fig. 6a, b) . Consistent with the results using NeuN staining, we do not detect TUNEL-positive cells in the striatum (data not shown). As ascertained from NeuN immunohistochemistry, there is no increase in pyknotic nuclei or TUNEL staining in MeCP2-Tg cortex at 10 weeks (data not shown), confirming that neuronal loss occurs at some point after 10 weeks of age.
Selective Upregulation of GFAP Expression in MeCP2-Tg Mice
We used GFAP immunostaining to evaluate the status of astrocytes in the MeCP2 brain. Interestingly, at 15 weeks of age, MeCP2-Tg mice consistently display a robust increase in GFAP staining and GFAP staining intensity in the cortex and hippocampus (Fig. 7a) . While the increase in GFAP staining is not generally observed in the cerebellum, in a few mice that displayed a severe phenotype and high GFAP upregulation in the cortex and hippocampus, some increase is observed even in the cerebellum at 15 weeks (data not shown). Interestingly, we have noted an increase in GFAP limited to lobe 7 of the cerebellum (data not shown). Other brain regions showed no increase in GFAP staining. Two aspects of the increased GFAP staining in the somatomotor cortex are interesting: (1) the increase in staining is variable and (2) while all MeCP2-Tg mice displayed increased GFAP staining, many had staining only in the outer half (pial half) or outer third or high aggregations of staining in this area of the cortex beginning around 10 weeks of age (Fig. 7a, e) . Thus, the pattern of elevated GFAP staining correlates with the location of where most neuronal loss is observed. Increased GFAP expression was confirmed by Western blot analysis (Fig. 7b) . RT-PCR analysis also revealed elevated GFAP messenger RNA Fig. 2 MeCP2-Tg (Tg) male mice display behavioral impairments and have increased brain weight. a Quantification of paw-clasping at 6, 9, 12, and 15 weeks of age (n = 9-20). b, c Hindlimb and forelimb grip strength at 6, 9, 12, and 15 weeks of age (n = 6) d Latency to fall using ROTOR-ROD. Quantification at 6 weeks (n = 6). e Locomotor analysis at 6, 9, 12, and 15 weeks of age (n = 9-32). f Y-maze entries at 6 and 15 weeks of age (n = 6). g Novel Object Recognition Test at 9 and 15 weeks (n = 6). h, i Body weight and brain weight measurements at 10 and 15 weeks (n = 12-32). j Brain to body weight ratios at 10 and 15 weeks (n = 12-32) (mRNA), suggesting that this is transcriptionally mediated (Fig. 7c) . GFAP immunostaining is often used to evaluate neuroinflammation that typically occurs after neuronal loss. In models of neurodegenerative disease as well as in the brains of patients, astrocyte activation and gliosis is a response to the degeneration of neurons and is limited to the area surrounding the dying neurons [27] . As described above and shown in Fig.  7a , increased GFAP staining is concentrated in the upper layers and can extend down through the lower layers of the MeCP2-Tg cortex. More interestingly, the increase in GFAP staining is observed in the MeCP2 cortex and hippocampus even at 10 weeks, when neuronal loss is not detectable (Fig. 7e ). Western blot analysis shows a slight increase in GFAP expression in the cortex and hippocampus of 10-week-old MeCP2-Tg mice (Fig. 7d) . The upregulation of GFAP before the commencement of neuronal loss argues against it being part of a neuroinflammatory response, which generally results from neurodegeneration. No increase in GFAP expression is observed in the MeCP2-Tg cortex or hippocampus of MeCP2-Tg mice at 3 weeks (data not shown).
Staining with Iba-1, a marker for microglia, reveals no increase in Iba1-positive cell numbers or expression in the MeCP2-Tg cortex at 15 weeks confirming the lack of a neuroinflammatory response (Fig. 8a, b) . Furthermore, the morphology of Iba1-positive cells in the MeCP2-Tg cortex is not different from those in the wild-type cortex, indicating that they are not activated (Fig. 7a) . Levels of glutamine synthase or GLT-1 transporter are also unchanged in MeCP2-Tg mice, indicating that the GFAP increase is not due to astrogliosis (Fig. 8c, d ). In contrast, the expression of GLAST/EAAT1 glutamate transporter is reduced in MeCP2-Tg mice (Fig. 8e) . Reduced GLAST1 expression has been shown to cause seizures in mice and humans and explains the seizures observed in patients with MeCP2 triplication syndrome [28, 29] . GFAP Is Upregulated in the Spinal Cord Earlier Than in the Brain The motor impairment detected by grip strength and rotorod assays at 6 weeks led us to examine whether abnormalities in the spinal cord precede those in the brain. Indeed, examination of the spinal cord shows increased GFAP staining even at 6 weeks (Fig. 9a) . The increase was more pronounced in the lumbar portion compared with the cervical portion of the spinal cord, consistent with hindlimbs being selectively affected at 6 weeks. Interestingly, we did detect a decrease in NeuN+ cells in the dorsal horn and an increase in active-caspase-3 staining revealing cell death in the dorsal horn at 6 weeks (Fig. 9b, c) . These results suggest that neurological impairment at 6 weeks could be due to degeneration in the spinal cord. Analyses of the spinal cord of MeCP2-Tg mice at 3 weeks revealed no increase in GFAP, suggesting that the increase occurred between 3 and 6 weeks (data not shown). Similarly, no motor impairment was discernible at 3 weeks (data not shown).
Selective Upregulation of Tau Expression in MeCP2-Tg Mice MeCP2 regulates microtubule structure and dynamics both in astrocytes and neurons [30, 31] . We examined the expression of the microtubule-associated protein MAP2, which is localized mainly in dendrites, and Tau, which is present mainly in axons. Expression of MAP2a and MAP2b is unaltered in the MeCP2-Tg brain (Fig. 10a) . However, Tau expression is significantly increased in the cortex, hippocampus, and to a lesser degree, the cerebellum of MeCP2-Tg mice (Fig. 10b) . Furthermore, the ON4R and 2N4R isoforms of Tau increase significantly in the cortex and hippocampus (Fig. 10c) . The extent of increase varied, as described above for GFAP staining. As observed with total Tau, levels of Tau phosphorylated at Ser262 (Fig. 10d) and Ser404 (not shown) increased. However, when p-Tau is expressed as a ratio of Tau, there is no significant change in Tau phosphorylation at Ser262 (Fig. 10d) or Ser404 (not shown). In contrast to the elevation in GFAP mRNA, Tau mRNA is not increased in MeCP2-Tg brain (Fig. 10e) , suggesting that the increase in Tau protein is mediated posttranscriptionally and likely to be due to enhanced protein stability.
Astrocytes Trigger Excitotoxic Death in MeCP2-Tg Mice
The finding that increased expression of GFAP precedes the upregulation of Tau and neurodegeneration in the cortex of MeCP2-Tg mice suggests that astrocytic dysfunction could trigger disease pathogenesis in the brain, possibly through the release of a neurotoxic factor. Contribution of an astrocyte-released neurotoxic factor has been implicated in the pathogenesis of several neurodegenerative diseases. To investigate the possibility that an astrocyte-derived factor contributes to neuronal death in the MeCP2-Tg brain, we expressed MeCP2 (both isoforms, E1 and E2, individually and in combination) in primary astrocytes cultured from the cortex of wild-type mice. We exposed wild-type cortical neurons to conditioned medium from these MeCP2-overexpressing astrocytes, henceforth referred to as MeCP2-ACM. While MeCP2-ACM from both E1 and E2 overexpressing astrocytes was toxic, expressing both isoforms (E1 + E2) showed highest toxicity with over 50% of the neurons dying after 48 h (Fig. 11a) . As observed with normal astrocytes overexpressing MeCP2, ACM from astrocytes cultured from MeCP2-Tg mice was also toxic to wildtype cortical neurons (Fig. 11b) . We next transduced astrocytes cultured from the cerebellum with MeCP2. MeCP2-ACM from cerebellar astrocytes displayed no toxicity when added to cortical neurons (not shown). Similarly, MeCP2-ACM from the U251 astrocyte cell line (not shown) had no effect on the viability of cortical neurons. These findings indicate that the neurotoxic factor was produced selectively by cortical astrocytes. Heat inactivation and freeze-thawing of cortical MeCP2-ACM had no effect on its neurotoxic effect (data not shown), suggesting that the neurotoxic factor >was not a protein. We explored the possibility that the factor was glutamate, which at elevated levels would cause excitotoxicity via overstimulation of NMDA/AMPA receptors. Consistent with excitotoxicity, the NMDAR antagonist, MK-801 (blocks pore of NMDAR), inhibits neurotoxicity by MeCP2-ACM (Fig. 11a) . Toxicity by ACM from cortical neurons cultured from MeCP2-Tg mice was also blocked by MK-801 (Fig. 11b) .
Analysis of GFP-ACM and MeCP2 ACM from neuronal, astrocytic, and mixed cultures revealed that the increase in extracellular glutamate concentration was dependent on the presence of astrocytes (Fig. 11c) .
Chronic excitotoxicity is an important contributor in slow-progressing neurodegenerative diseases, including Alzheimer's disease, Huntington's disease, and ALS. Interestingly, studies by other labs have found that Tau expression is increased by excitotoxicity, suggesting that the elevation in Tau in the MeCP2-Tg brain may be due to excitotoxicity induced by astrocyte dysfunction [32] [33] [34] . However, treatment of cortical neurons with ACM from astrocytes overexpressing MeCP2 or from male MeCP2-Tg mice induced Tau only slightly, suggesting that cell autonomous changes in neurons resulting from extended elevation of MeCP2 is the major contributor to increased Tau (Fig. 11d, e) .
Female MeCP2-Tg Mice Express Elevated MeCP2 but Display
Normal GFAP and Tau Expression In humans, females with MECP2 triplication syndrome suffer mild psychiatric symptoms or are asymptomatic. This is believed to be due to heavily skewed inactivation of the abnormal X-chromosome permitting expression predominantly from the single normal X chromosome. We find that female transgenic mice express MeCP2 at about two times higher than normal (1.94-fold) (Fig. 12a) , whereas male MeCP2-Tg expression was about three times higher (3.3-fold) (Fig. 1c) . However, the approximately 2-fold higher expression of MeCP2 in females suggests that, at least in mice, skewing of the defective chromosome is inefficient. We verified that the human transgene was efficiently expressed in female MeCP2-Tg mice by RT-PCR (Fig. 12b) . Despite expressing about twice the level of MeCP2, ACM from the cortex of female MeCP2-Tg mice did not contain elevated glutamate and was not toxic to cortical neurons (Fig. 12c-e) . Moreover, the increased GFAP and reduced GLAST displayed by male MeCP2-Tg astrocytes was not observed in female MeCP2-Tg astrocytes (Fig. 12f) . This suggests that for elevation of GFAP and disruption of glutamate homeostasis in astrocytes, expression of MeCP2 has to cross a certain threshold, which is not reached in female MeCP2-Tg astrocytes. To test this, we overexpressed MeCP2 in normal (WT) male and female astrocytes. We found that ACM from both WT male and female astrocytes overexpressing MeCP2 was toxic to cortical neurons (data not shown). In MeCP2 Tg mice, when we compared the increase in Tau expression to the fold change in MeCP2 levels, we found a correlation in MeCP2-Tg male mice (r 2 = 0.8) but not in MeCP2-Tg female mice (Supplemental Fig. 2 ). Taken together, these results suggest regulation of GFAP and Tau expression, and by extension, the gender-specific neurological abnormalities in MeCP2-Tg mice requires highly elevated MeCP2 which is not attained in female mice and cells because of expression from the normal X chromosome.
Discussion
We report that male MeCP2-Tg mice display macrocephaly and progressive neurological deficits, including motor and cognitive deficits, ataxia, and a severely shortened life span. These are abnormalities also seen in patients with MECP2 duplication and triplication syndrome. Seizures, another common issue in patients, have previously been described in MeCP2-Tg mice [14] . We find that hindlimbs are selectively weakened in MeCP2-Tg mice. Greater effect on lower limb strength has also been described in MECP2 triplication Fig. 7 Increase in GFAP expression in MeCP2-Tg brain precedes neuronal loss but occurs in the same regions that subsequently display neuronal loss. a GFAP staining and measurement of staining intensity in the CTX, HIP, and CBM of 15-week-old WT and MeCP2-Tg mice (n = 9). CTX shows lowmagnification image (left panels) and high-magnification images (right panels). The white box in low-magnification image denotes location of high-magnification image. b Western Blot and quantification showing expression of GFAP in CTX, HIP, and CBM of 15-week-old WT and MeCP2-Tg mice (n = 7). c GFAP RT-PCR in the CTX, HIP, and CBM of 15-week-old Tg mice. Eighteen seconds was used to normalize cDNA. d Western Blot and quantification showing expression of GFAP in the CTX, HIP, and CBM of 10-week-old WT and MeCP2-Tg mice (n = 5). ERK1/2 serves as a loading control. e GFAP staining and measurement of staining intensity in the CTX, HIP, and CBM of 15-week-old WT and MECP2-Tg mice (n = 6). For CTX, upper panels are lower-magnification images and lower panels are higher-magnification images. The white box in the lowermagnification images denotes locations of the highermagnification images syndrome patients [8] . As in patients, some variability in symptom severity and non-neuronal abnormalities, such as constipation, are also observed in MeCP2-Tg mice. Female MeCP2-Tg mice do not display discernible neurological deficits, recapitulating the situation in humans where females are asymptomatic or mildly affected.
Although we have observed abnormalities in the spinal cord of MeCP2-Tg mice even at 6 weeks of age that likely contribute to motor impairment, in this study we have focused on the brain. MeCP2-Tg mice display neuronal loss in the cortex and hippocampus. Within the cortex, upper layers are more affected, while within the hippocampus, the CA1 region is most affected. Within the cerebellum, Purkinje neurons suffer degeneration but granule neurons are unaffected. These results indicate selectivity in vulnerability to elevated MeCP2. Although confirmation will depend on careful analysis of patient tissue, which is currently unavailable, based on the neuronal death in MeCP2-Tg mouse brain we propose that MeCP2 duplication/triplication syndrome is a neurodegenerative disorder. Our conclusion is supported by MRI studies describing cortical atrophy in patients with MECP2 duplication syndrome [9, 11, 12] . Diffuse loss of neurons in the cortex and extensive loss of Purkinje neurons has also been reported [13, [35] [36] [37] .
A recent study described abnormal dendritic arborization and spine morphology in MeCP2 transgenic mice, but no cell loss [38] . However, analyses of cell numbers in this study were done on 9-week-old mice an age at which there is no neuronal death even in our analyses. Another major difference between our study and the one by Jiang et al. was that in their study the MeCP2-Tg1 line was used. This line expresses MeCP2 at about two times the normal level and displays symptoms that are relatively mild compared to patients with MeCP2 duplication/triplication syndrome [14] . In our analyses of MeCP2-Tg3 line, we found that MeCP2 protein is expressed at 3.3 times the normal level, which agrees with the 3-5-fold higher expression that Jackson Labs reports in their data sheet for this transgenic line. Thus, these mice express MeCP2 at a level that is slightly higher than MeCP2 triplication disorder patients. As observed in a variety of other mouse genetic models of neurodevelopmental and neurodegenerative disorders, mimicking of human abnormalities in mice often requires a higher level of mutant gene expression than in patients. Although it would be interesting to analyze other models of MECP2 duplication/triplication syndrome, like the Tg-1 line, in which MeCP2 is expressed at patient levels, the failure of such mouse models to recapitulate key features and the severity of the human disorders suggests that molecular and cellular alterations responsible for the neurological abnormalities do not occur in these mouse models. Whether analyses of these mouse models will provide a substantive understanding of disease mechanisms is therefore debatable.
MeCP2-Tg mice display highly elevated expression of GFAP in the hippocampus and cortex. In a few older mice displaying more severe neurological deficits, a small increase in GFAP is observed in the cerebellum also. This suggests that while the cortex and hippocampus are most vulnerable, the increase in GFAP could occur in other brain parts at late stages of the disorder. In fact, results of three separate microarray analyses by the Zoghbi lab using amygdala, cerebellum, and hippocampus from MeCP2-Tg mice revealed that GFAP mRNA upregulation occurs in all three brain parts, although this finding was not noted or pursued further [39] [40] [41] . While increased GFAP is generally regarded as a marker of neuroinflammation, it can occur independently of a neuroinflammatory response and by itself cause neurological deficits. This occurs in Alexander disease (AxD), an astrogliopathy caused by mutations in GFAP resulting in its accumulation in astrocytes of the hippocampus and cortex [42, 43] . Patients with type-1 AxD display macrocephaly, seizures, developmental retardation, hypoactivity, and shortened life span. While the primary cause is astrocyte dysfunction, type-1-AxD patients display variable neuronal loss in the hippocampus, cortex, and striatum [18, 43, 44] . The neurological abnormalities and early death of AxD can be recapitulated in mice and flies by overexpression not only of mutant forms of GFAP but also of normal GFAP [18, [45] [46] [47] . In AxD, a reduction in the level of the GLT1 glutamate transporter in vulnerable brain regions has been suggested to affect glutamate clearance leading to excitotoxic death of neurons [48] [49] [50] . Similarly, in MeCP2-Tg mice, the increased expression of GFAP and reduction in GLAST is most pronounced in the MeCP2-Tg cortex and hippocampus, where neuronal loss occurs subsequently. Our results suggest that rather than being a disorder that is primarily neuronal in nature, the trigger for disease pathogenesis in MECP2 triplication disorder is astroglial dysfunction. If so, MECP2 triplication disorder would join a growing list of neurodevelopmental and neurodegenerative disorders in which glia play an essential role in disease pathogenesis [51, 52] .
Another novel observation is the increased expression of Tau in the MeCP2-Tg brain. In both Drosophila and mice, overexpression of Tau in the CNS results in progressive neurodegeneration [15, 16, 32, 34, 53] . Interestingly, expression of Tau mRNA is not elevated, indicating that the increase in protein occurs by a posttranscriptional mechanism. Consistently, Tau mRNA was not identified as differentially expressed in any of the microarray gene expression studies conducted by the Zoghbi lab [39] [40] [41] . Although our analysis of two sites, Ser 262 and Ser404, revealed no increase in the extent of Tau phosphorylation in MeCP2-Tg mice, it is possible that phosphorylation is elevated at other residues.
As observed in vivo, GFAP is elevated in astrocytes cultured from the cortex of MeCP2-Tg mice and even in normal cortical astrocytes in which MeCP2 is overexpressed. Furthermore, CM from these astrocytes induces death of normal cortical neurons. In contrast, CM from cerebellar astrocytes is not toxic to cortical neurons, suggesting that cortical astrocytes are more vulnerable to elevated MeCP2. Neurotoxicity from cortical MeCP2-Tg astrocyte CM is accompanied by Tau upregulation. The abrogation of CMmediated neurotoxicity by MK-801, which also inhibits the increase in Tau expression, suggests that both Tau induction and neuronal death are due to NMDA receptor-mediated excitotoxicity. Previous studies have found that upregulation of Tau following excitotoxic insult can be blocked by MK801 and other NMDA receptor antagonists [54] [55] [56] [57] . Furthermore, lowering Tau levels can protect against excitotoxicity, suggesting that excitotoxic neuronal loss requires Tau upregulation [58, 59] . Accumulating evidence suggests that reducing Tau also can reduce seizures and protect against neurological and cognitive deficits in multiple mouse models of Alzheimer's disease (AD) and traumatic brain injury [60] [61] [62] [63] [64] . Unlike CM from male MeCP2-Tg astrocytes, CM from female astrocytes does not induce Tau in neurons and is not neurotoxic. Although this could be because of highly skewed X-chromosome inactivation of the chromosome with the transgene, we were surprised to find that the MeCP2 transgene is efficiently expressed in the cortex of female MeCP2-Tg mice. While lower than in male MeCP2-Tg mice, Western blot analysis revealed that the total level of MeCP2 in the Fig. 11 Conditioned media from cortical astrocytes infected with MeCP2 adenovirus and conditioned media from cortical astrocytes from male MeCP2-Tg mice kills cortical neurons. a, b Pretreatment with an NMDA receptor antagonist, MK801 (1 μM), prevents astrocyte conditioned media from killing cortical neurons (n = 3). c Glutamate levels are increased in the media of pure astrocyte cultures or mixed neuronal + astrocyte cultures overexpressing MeCP2, but not pure neuronal cultures overexpressing MeCP2. d Tau expression is increased in cortical neurons after treatment with astrocyte conditioned media from astrocytes overexpressing MeCP2 (n = 2). e Tau expression is increased in cortical neurons after treatment with astrocyte conditioned media from male WT or MeCP2-Tg mice (n = 2) female MeCP2-Tg cortex is almost 2-fold higher than normal. Although further analyses is needed, our finding that female MeCP2-Tg mice express the transgene efficiently and produce elevated MeCP2 argues against the general belief that women with MeCP2 duplication or triplication on the X chromosome are largely asymptomatic because of highly skewed Xchromosome inactivation. A likely explanation is that in both humans and in mice, MeCP2 expression has to cross a certain threshold before pathological mechanisms are triggered. Because females with MECP2 gene duplication also express MeCP2 from the normal X chromosome, the total level of MeCP2 is lower than in males and thus lower than the pathological threshold. In the MeCP2-Tg mice, the threshold is likely to be~3-fold higher than normal, which is crossed in male MeCP2-Tg mice, but not female mice. This may also explain why even male mice of the TG-1 line of Collins et al. [14, 38] , which have an~2-fold elevation in MeCP2, do not display the severe phenotype observed in MeCP2-Tg mice (TG-3 line) and patients. Indeed, in preliminary experiments, we find that when MeCP2 is overexpressed in normal female cortical astrocytes (at levels that are several fold higher than normal), high levels of glutamate are present in the ACM and the ACM is toxic to neurons (data not shown). Also conceivable however, and not mutually exclusive with the threshold hypothesis, is that female astrocytes (and perhaps neurons) may have protective mechanisms capable of preventing astrocyte dysfunction and excitoxicity. One candidate for such protection could be estrogens. . c Glutamate homeostasis is affected in male MeCP2-Tg mice but not in female MeCP2-Tg mice (n = 3). d Conditioned media from MeCP2-Tg female cortical astrocytes does not affect cortical neuron survival (n = 3), and there is no significant change in glutamate levels in conditioned media from WT and MeCP2-Tg female astrocytes (n = 3). e MeCP2-Tg males display elevated glutamate levels with increased MeCP2 expression (n = 7), while MeCP2-Tg females do not (n = 5). Transgenic animals are denoted in boxes. f Increased GFAP expression and decreased GLAST in male, but not female, MeCP2-Tg mice. ERK 1/2 was used as a loading control In summary, we propose for the first time that MECP2 triplication syndrome is a neurodegenerative disorder. The severe cognitive impairment and ataxia suffered by patients with MECP2 duplication and triplication syndrome is consistent with neuronal loss in the cortex, hippocampus, and cerebellum. We suggest that astrocytic dysfunction resulting from an upregulation of GFAP leads to defective glutamate homeostasis, which through excitoxicity and an elevation of Tau levels kills neurons (Fig. 13) . Reduction of Tau has been shown to reduce seizures, excitotoxicity, and neurodegeneration. Pharmacological agents, anti-sense oligonucleotides, or CRISPR-mediated approaches targeting Tau or GFAP may represent an attractive therapeutic approach for MECP2 duplication/triplication syndrome. Blocking excitotoxicity by inhibition of NMDA receptors could be another effective approach to treat this devastating disorder. Fig. 13 Model for MeCP2 triplication syndrome. Elevated MeCP2 resulting from gene duplication/triplication leads to an upregulation of GFAP expression in the cortex and hippocampus, which along with a downregulation of GLAST1 results in dysfunction of astrocytes. The reduced GLAST1 affects glutamate clearance thus promoting excitotoxicity, which increases levels of Tau. The effects of elevated Tau along with excitotoxicity cause the death of cortical and hippocampal neurons. Increased Tau could also result from the high expression of MeCP2 in neurons. The loss of neurons in the cortex, hippocampus, and cerebellum result in severe cognitive and behavioral deficits, seizures leading to premature death
